Literature DB >> 11102983

Novel thymidylate synthase enhancer region alleles in African populations.

S Marsh1, M M Ameyaw, J Githang'a, A Indalo, D Ofori-Adjei, H L McLeod.   

Abstract

Thymidylate synthase (TS) regulates the production of DNA synthesis precursors and is an important target of cancer chemotherapy. A polymorphic tandem repeat sequence in the enhancer region of the TS promoter was previously described, where the triple repeat gives higher in vitro gene expression than a double repeat. We recently identified ethnic differences in allele frequencies between Caucasian and Asian populations. We now describe assessment of genotype and allele frequencies of the TS polymorphism in 640 African (African American, Ghanaian and Kenyan) and Caucasian (UK, USA) subjects. The double and triple repeat were the predominant alleles in all populations studied. The frequency of the triple repeat allele was similar between Kenyan (49%), Ghanaian (56%), African American (52%), American Caucasian (54%) and British Caucasian (54%) subjects. However, two novel alleles contained 4 and 9 copies of the tandem repeat. These novel alleles were found at a higher allele frequency in African populations (Kenyan 7%, Ghanaian 3%, African American 2%) than Caucasians (UK 1%, USA 0%). The novel alleles identified in this study decrease in frequency with Western migration, while the common alleles are relatively stable. This is a unique example suggesting the influence of multiple selection pressures within individual populations. Hum Mutat 16:528, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102983     DOI: 10.1002/1098-1004(200012)16:6<528::AID-HUMU11>3.0.CO;2-W

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  19 in total

Review 1.  Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

Authors:  Norman H Lee
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

2.  TYMS and DPYD polymorphisms in a Turkish population.

Authors:  H S Süzen; N Yüce; G Güvenç; Y Duydu; T Erke
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

3.  Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population.

Authors:  M Acuña; L Eaton; L Cifuentes; D Massardo
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 4.  Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.

Authors:  Christine M Hartford; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2007-09       Impact factor: 2.533

5.  Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.

Authors:  Kong M Li; Laurent P Rivory; Janelle Hoskins; Rohini Sharma; Stephen J Clarke
Journal:  Br J Clin Pharmacol       Date:  2006-07-07       Impact factor: 4.335

Review 6.  Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

7.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

8.  Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer.

Authors:  Kai-Huan Yu; Wei-Xing Wang; You-Ming Ding; Hui Li; Ze-Sheng Wang
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

Review 9.  Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.

Authors:  Peter H O'Donnell; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

Review 10.  Impact of pharmacogenomics on clinical practice in oncology.

Authors:  Sharon Marsh
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.